Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma

被引:26
|
作者
Gupta, Shaloo [1 ]
Abouzaid, Safiya [2 ]
Liebert, Ryan [1 ]
Parikh, Kejal [2 ]
Ung, Brian [2 ]
Rosenberg, Aaron S. [3 ]
机构
[1] Kantar Hlth, Hlth Outcomes Practice, 11 Madison Ave,12th Floor, New York, NY 10010 USA
[2] Celgene Corp, US Hlth Econ & Outcomes Res, Summit, NJ USA
[3] Univ Calif Davis, Davis Comprehens Canc Ctr, Div Hematol & Oncol, Sacramento, CA 95817 USA
来源
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2018年 / 18卷 / 03期
关键词
Direct costs; Functional impairment; Health care resource usage; Quality of life; Work productivity impairment; FUNCTIONAL ASSESSMENT; WORK PRODUCTIVITY; SYMPTOM BURDEN; LIFE HRQOL; FACT-G; THERAPY; IMPACT; TRANSPLANTATION; VALIDATION; VALIDITY;
D O I
10.1016/j.clml.2018.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It is unclear how medication adherence affects the burden of multiple myeloma (MM). Overall, 162 adults with MM completed an online survey. Better medication adherence related to less impairment to work productivity and functioning, lower out of pocket costs, and fewer office visits. With increased survival, considering the quality of life for patients with MM will be essential. Background: The present study characterized the effect of multiple myeloma (MM) on work productivity, health care resource usage, and out of pocket costs (OOPCs) and examined the association of adherence with quality of life (QoL) and productivity loss. Materials and Methods: The present cross-sectional study included 162 patients categorized by their 4-item Morisky Medication Adherence Scale (MMAS-4) score (4 vs. <= 3). Online surveys included the Work Productivity and Activity Impairment questionnaire, Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM), and MM-specific questions. Results: On average, patients reported FACT-MM scores of 98.5 +/- 29.3, absenteeism of 18.3% +/- 17.8%, presenteeism of 51.8% +/- 30.2%, overall work productivity impairment of 57.3% +/- 31.7%, and activity impairment of 49.9% +/- 29.5% in the previous 7 days. During the previous 3 months, the mean OOPCs were $709 +/- $1307; prescription medications accounted for 55% of these costs. Patients attended 4.1 +/- 4.6 visits to oncologists or hematologists during that time, which accounted for 45% of the OOPCs. Patients spent an average of 6.8 +/- 8.3 hours at MM-related monthly appointments, and 35.2% reported frustration while at the doctor's office. Patients with an MMAS-4 score of 4 reported higher FACT-MM scores (106.9 vs. 89.2; P < .001). Patients with an MMAS-4 score of <= 3 reported greater activity impairment (56.5% vs. 39.8%; P = .015) and feeling overwhelmed or frustrated with rescheduling MM appointments (64.0% vs. 26.0%; P = .002). Conclusion: MM was associated with significant workplace and functional impairment, high OOPCs, and frequent office visits. High medication adherence was associated with better outcomes across these domains. As survival for patients with MM improves, patient QoL should be considered to enhance these outcomes.
引用
收藏
页码:210 / 218
页数:9
相关论文
共 50 条
  • [1] Assessing the Effect of Adherence on Patient-reported Outcomes and Out of Pocket Costs Among Patients With Multiple Myeloma (vol 18, pg 210, 2018)
    Gupta, Shaloo
    Abouzaid, Safiya
    Liebert, Ryan
    Parikh, Kejal
    Ung, Brian
    Rosenberg, Aaron S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (08): : 552 - 552
  • [2] Assessing the Effect of Injectable or Oral Routes of Treatment Administration on Patient-Reported Outcomes and out-of-Pocket Costs Among Patients with Multiple Myeloma
    Gupta, Shaloo
    Abouzaid, Safiya
    Liebert, Ryan
    Parikh, Kejal
    Rosenberg, Aaron S.
    BLOOD, 2016, 128 (22)
  • [3] Assessing the Effect of Pomalidomide or Carfilzomib Treatment on Patient-Reported Outcomes Among Patients With Relapsed/Refractory Multiple Myeloma
    Gupta, Shaloo
    Clancy, Zoe
    Copher, Ronda
    Rosenberg, Aaron Seth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E268 - E269
  • [4] ASSOCIATION BETWEEN ADHERENCE TO LENALIDOMIDE AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE SEARCH
    Ramasamy, K.
    von Lilienfeld-Toal, M.
    Maisel, C.
    Gustavsson, B.
    Back, K.
    Glasmacher, A.
    Leleu, X.
    VALUE IN HEALTH, 2023, 26 (12) : S6 - S7
  • [5] Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel
    Oswald, Laura B.
    Gudenkauf, Lisa M.
    Li, Xiaoyin
    De Avila, Gabriel
    Peres, Lauren C.
    Kirtane, Kedar
    Gonzalez, Brian D.
    Hoogland, Aasha I.
    Nguyen, Oanh
    Rodriguez, Yvelise
    Baz, Rachid C.
    Shain, Kenneth H.
    Alsina, Melissa
    Locke, Frederick L.
    Freeman, Ciara
    Castaneda Puglianini, Omar
    Nishihori, Taiga
    Liu, Hien
    Blue, Brandon
    Grajales-Cruz, Ariel
    Jim, Heather S. L.
    Hansen, Doris K.
    CANCERS, 2023, 15 (19)
  • [6] Patient-reported outcomes regarding radiation therapy in patients with multiple myeloma
    Nanda, Ronica
    Boulware, David
    Baz, Rachid
    Portman, Diane
    Yu, H. Michael
    Jim, Heather
    Johnstone, Peter A. S.
    ACTA ONCOLOGICA, 2020, 59 (08) : 983 - 987
  • [7] ASSESSING PATIENT-REPORTED OUTCOMES AND WORK PRODUCTIVITY ALONG THE MULTIPLE MYELOMA (MM) PATIENT JOURNEY
    Gupta, S.
    Clancy, Z.
    Doane, M. J.
    VALUE IN HEALTH, 2018, 21 : S18 - S18
  • [8] Assessment tools for patient-reported outcomes in multiple myeloma
    Ting Wang
    Qin Lu
    LeiWen Tang
    Supportive Care in Cancer, 2023, 31
  • [9] Assessment tools for patient-reported outcomes in multiple myeloma
    Wang, Ting
    Lu, Qin
    Tang, LeiWen
    SUPPORTIVE CARE IN CANCER, 2023, 31 (07)
  • [10] Importance of Assessing Patient-Reported Outcomes With Salvage Autologous Transplantation in Relapsed Multiple Myeloma
    Shaw, Bronwen E.
    D'Souza, Anita
    Lee, Stephanie J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (19)